DDrare: Database of Drug Development for Rare Diseases

309. 進行性ミオクローヌスてんかん
［臨床試験数：11，薬物数：15（DrugBank：2），標的遺伝子数：4，標的パスウェイ数：9］

Searched query = "Progressive myoclonus epilepsy", "Unverricht-Lundborg disease", "Lafora disease", "Benign adult familial myoclonus epilepsy", "BAFME"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide; (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide; BRIVARACETAM; BRV 2.5 mg; BRV 25 mg; BRV 50 mg; Brivaracetam; Brivaracetam 25 mg; Brivaracetam 50 mg; Intravenous immunoglobulin; ROPINIROLE HYDROCHLORIDE; Requip; Ropinirole; Ropinirole hydrochloride; Ucb 34714

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00368251 (ClinicalTrials.gov)	November 2006	23/8/2006	Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (= 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease	Unverricht-Lundborg Disease	Other: Placebo;Drug: BRV 2.5 mg;Drug: BRV 25 mg;Drug: BRV 50 mg	UCB Pharma	NULL	Completed	16 Years	N/A	All	56	Phase 3	United States;Canada;Finland;France;Israel;Russian Federation;Serbia;Tunisia;Former Serbia and Montenegro

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00368251
(ClinicalTrials.gov)

November 2006

23/8/2006

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (= 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease

Unverricht-Lundborg Disease

Other: Placebo;Drug: BRV 2.5 mg;Drug: BRV 25 mg;Drug: BRV 50 mg

UCB Pharma

NULL

Completed

16 Years

N/A

All

Phase 3

United States;Canada;Finland;France;Israel;Russian Federation;Serbia;Tunisia;Former Serbia and Montenegro